Therapies for cancer using RLIP76

Abstract

The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells. Medicines may be in the form of antibodies, si-RNA and small molecules that recognize the region.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application is a continuation-in-part of prior U.S. application Ser. No. 10 / 714,506, filed Nov. 13, 2003, herein incorporated by reference, which claims the benefit of U.S. Provisional Patent Application No. 60 / 425,917, filed Nov. 13, 2002. This application is a continuation-in-part of prior U.S. application Ser. No. 10 / 713,578, filed Nov. 13, 2003, herein incorporated by reference, which claims the benefit of U.S. Provisional Patent Application No. 60 / 425,814, filed Nov. 13, 2002.STATEMENT REGARDING FEDERALLY SPONSORED APPLICATIONS [0002] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant No. NIH 2-R01-CA77495, Grant No. NIH CA 104661.REFERENCE TO A SEQUENCE LISTING [0003] This application incorporates by reference sequence listing material included on computer readable form and i...

AI Technical Summary

Benefits of technology

[0007] As provided herein, RLIP76 is a membrane associated protein and a critical as well as predominant regulator of transport in cancerous cells or those undergoing uncontrolled cells growth. Targeting therapies against RLIP76 directly effects RLIP76 transport activity and reduce the number and / or potency of such cells undergoing uncontrolled cell growth in subjects having such uncontrolled and growing cells.

[0008] The present invention provides for compositions that target RLIP76 and reduce the number and / or potency of cells undergoing uncontrolled cell growth. Compositions comprise a region homologous to a portion of a ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth.

Problems solved by technology

Current therapies for human cancers are generally unsatisfactory because of a high rate of failure and excessive side-effects.

Side effects are generally significant and result, in part, because few current therapies are targeted to cancerous cells alone.

Images